文献速递淋巴瘤白血病

接受伊布替尼治疗的慢性淋巴细胞白血病患者中弥漫性大B细胞淋巴瘤型Richter转化的危险因素与结局

Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.
PubMed 文献 · Leukemia · 2025-06-25

本研究在976例接受伊布替尼治疗的慢性淋巴细胞白血病(CLL)患者中分析弥漫性大B细胞淋巴瘤型Richter转化(DLBCL-RT)的发生率与危险因素。83例(8.5%)发生DLBCL-RT,7年发生率为15.6%。年龄<70岁(HR 1.98,p=0.019)和TP53异常(HR 1.72,p=0.044)为独立预测因素,既往治疗有接近显著的趋势(HR 1.91,p=0.065)。

要点

  • 976例接受伊布替尼治疗的CLL患者中83例(8.5%)发生DLBCL-RT,7年发生率为15.6%。
  • DLBCL-RT诊断时中位总生存期为4.7个月,细胞减少是唯一显著不良预后因素(HR 1.68)。
  • 年龄<70岁、TP53异常和既往治疗增加DLBCL-RT风险,风险因素数量对应发生率从4%到22.6%(p<0.0001)。

核心结论

  • 接受伊布替尼治疗的CLL患者中,年龄<70岁、TP53异常和既往治疗者发生DLBCL-RT风险增加,需要密切监测。

研究设计与样本

  • 研究纳入976例接受伊布替尼治疗的慢性淋巴细胞白血病(CLL)患者,分析弥漫性大B细胞淋巴瘤型Richter转化(DLBCL-RT)的发生率、危险因素与结局。

主要发现

  • 83例(8.5%)患者记录到DLBCL-RT,7年发生率为15.6%。
  • 多数患者表现出侵袭性淋巴瘤的临床征象:83%有淋巴结增大,60%有细胞减少,98%在CT/PET上Suvmax值≥5。
  • 在有数据的患者中,83%为IGHV未突变,60%有TP53异常,26%有NOTCH1突变,10%归类于subset #8,82%为克隆相关性淋巴瘤。
  • 32%的患者对化学免疫治疗有反应。
  • 中位总生存期为4.7个月,DLBCL-RT诊断时细胞减少是唯一显著的不良生存因素(HR 1.68)。

临床怎么用

  • 作者认为,接受伊布替尼治疗的CLL患者中,年龄<70岁、TP53异常和既往治疗者发生DLBCL-RT风险增加,需要密切监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to define the incidence and risk factors for diffuse large B cell lymphoma variant of RT (DLBCL-RT) in 976 patients with CLL who received ibrutinib therapy. DLBCL-RT was recorded in 83 (8.5%) patients, with a 7-year 15.6% rate. Most patients exhibited clinical signs of aggressive lymphoma, enlarged lymph nodes in 83%, cytopenia in 60%, and Suvmax values ≥ 5 at CT/PET in 98%. Among patients for whom the data was available, 83% had unmutated IGHV, 60% TP53 disruption, 26% mutated NOTCH1, 10% were categorized in subset #8 and 82% had a clonally-related lymphoma. Response to chemoimmunotherapy was achieved by 32% of patients. Median OS was 4.7 months, with cytopenia at DLBCL-RT diagnosis being the only significant factor for inferior survival (HR, 1.68). In multivariable analysis, factors predictive for increased risk of DLBCL-RT were age <70 years (HR: 1.98, p = 0.019), TP53 disruption (HR: 1.72, p = 0.044), with a trend to significance for prior treatment (HR: 1.91, p = 0.065). According to the number of these risk factors, DLBCL-RT rate varied from 4% to 22.6% (p < 0.0001). In conclusion, patients with CLL receiving ibrutinib with age <70 years, TP53 disruption and previously treated are at increased risk for developing DLBCL-RT and deserve close monitoring.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pepe S, Vitale C, Giannarelli D, et al. Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes. Leukemia. 2025. PMID: 40562789. doi:10.1038/s41375-025-02666-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。